ERBB2 and breast cancer: Based on the fact that HER2-low BC has low or moderate HER2 expression and can benefit from new targeted drugs, some scholars proposed that HER2-low BC is different from HER2-zero, that is, different from luminal BC or triple-negative BC, and may be an independent subtype.